Rallybio Corporation Common Stock (RLYB)

FairStock Score: 68/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham investor, I start with durable earnings. Rallybio is a clinical-stage rare-disease company. In fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $212,000 and net loss was $8.3M. In fiscal 2025, the year ended 2025-12-31, revenue was $858,000 and net loss was $9.0M; in fiscal 2024, the year ended 2024-12-31, net loss was $57.8M; and in fiscal 2023, the year ended 2023-12-31, net loss was $74.6M. Then, in fiscal Q2 2026, the quarter ended 2026-06-30, net income was $43.7M and diluted EPS was $7.53. That swing makes the FairStock P/E of 2.09 at the 2026-10-13 close look optical, not proof of durable profits.

In plain English: Rallybio is a tiny clinical-stage biotechnology company trying to develop therapies for severe rare diseases. It has almost no revenue and has mostly lost money, though one recently filed quarter showed a large positive accounting profit and it has no debt. The stock price is near its accounting net worth and looks cheap on some simple measures, but the business is unproven, so that cheapness comes with high uncertainty.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer